Page 10 - RxExam's Naplex Theory Book Part 2

www.pharmacyexam.com Krisman

Dose Special Notes

Epoetin alfa 5). ESAs shortened overall survival and/or increased the risk of tumor
(Injection) progression or recurrence in clinical studies of patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or
dispense Epogen or Procrit to patients with cancer.

Darbepoetin 1. Patients with 1). Darbepoetin alfa (Aranesp) is an erythropoiesis-stimulating protein
Alfa CKD on dialysis: that is produced in Chinese hamster ovary (CHO) cells by recombinant
(Injection) 0.45 mcg/kg IV or DNA technology.
SC as a weekly
injection 2). Darbepoetin alfa (Aranesp) is indicated for the anemia due to:
OR
0.75 mcg/kg once a). Chronic Kidney Disease (CKD)
every 2 weeks. b). Chemotherapy in Patients With Cancer

2. Patients with 3). In controlled trials, patients experienced greater risks for death,
CKD NOT on serious adverse cardiovascular reactions, and stroke when
dialysis: administered erythropoiesis-stimulating agents (ESAs) to target a
0.45 mcg/kg IV or hemoglobin level of greater than 11 g/dL.
SC given once
every 4 weeks. 4). ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in clinical studies of patients with breast,
3. Chemotherapy non-small cell lung, head and neck, lymphoid, and cervical cancers.
induced anemia: Because of these risks, prescribers and hospitals must enroll in and
2.25 mcg/kg every comply with the ESA APPRISE Oncology Program to prescribe and/or
week SC until dispense Aranesp to patients with cancer.
completion of a
chemotherapy 5). An increased incidence of deep vein thrombosis, serious
course. cardiovascular events and strokes (especially in chronic renal failure
OR patients), pure red cell aplasia (PRCA), severe anemia, hypertension
500 mcg every 3 and seizure are reported side effects of Darbepoetin alfa (Aranesp).
weeks SC until
completion of a
chemotherapy
course.

Epoetin beta 1. Anemia due to 1). Epoetin beta methoxy polyethylene glycol (Mircera) is an
methoxy CKD: erythropoiesis-stimulating agent. It is indicated for the treatment of
propylene glycol 0.6 mcg/kg body anemia associated with chronic renal failure (CRF) in adults, including
(Injection)
weight given as a patients on dialysis and not on dialysis.
single IV or SC
injection once
every two weeks.

9